Fresenius Kabi Concedes On FDA Pegfilgrastim Chances
German Firm Also Rules Out Humira Interchangeability Designation
Fresenius Kabi is continuing to suffer from the longstanding effects of the US FDA backlog for onsite inspection reviews amid the coronavirus pandemic. Management discussed Kabi’s latest prospects on its proposed pegfilgrastim biosimilar, as well as adalimumab and tocilizumab.
You may also be interested in...
In the second part of Generics Bulletin’s exclusive interview with Fresenius Kabi’s senior vice president for biosimilars in the US, Ali Ahmed, he explains why Kabi is relishing the prospect of competing in pegfilgrastim and what the acquisition of mAbxience means for the company’s prospects and vision.
Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.
Fresenius Kabi’s Q1 call spanned its recent launch of a generic version of Takeda’s Velcade subcutaneous injectable to the company’s continued ambitions in biosimilars, with the German firm’s acquisition of a controlling stake in mAbxience scheduled to close by the middle of the year.